Literature DB >> 27473098

Liquid and softgel levothyroxine use in clinical practice: state of the art.

Camilla Virili1, Pierpaolo Trimboli2, Francesco Romanelli3, Marco Centanni4,5.   

Abstract

Levothyroxine is recognized as the treatment of choice for hypothyroidism. So far, the tablet levothyroxine has been the formulation almost exclusively used, even though an optimal daily dose of levothyroxine has been unsuccessfully sought and a consensus not achieved. Due to progressive use of a more individually tailored levothyroxine dose, increasing evidence has instead displayed that many gastrointestinal disorders, polypharmacy, and food interference may raise the daily levothyroxine requirement. In recent years, alternative levothyroxine formulations have become available and have rapidly gained attention because of their pharmacokinetic properties. This study aims to provide an overview regarding the use of softgel capsule and/or liquid levothyroxine solution while performing a review of published studies about such topic. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Google Scholar databases has been conducted to find published articles on this topic. The search algorithm was based on the combinations of the following terms: "oral solution" or "soft gel" or "liquid", and "levothyroxine". The computer search resulted in 75 articles; through a critical review of such titles and abstracts and a screening of their references lists, the review included 18 original articles relating to 800 patients treated with alternative formulations. Despite some limits, the results obtained using softgel and liquid levothyroxine were consistent with each other. In selected categories of levothyroxine-treated patients (pediatric, suffering from hypo-achlorhydria, polypharmacy, undergone bariatric surgery, fed through enteric tube) these new formulations have shown promising attributes in improving a treatment that needs to be individually tailored.

Entities:  

Keywords:  Hypothyroidism; Liquid; Softgel; Thyroxine malabsorption; Thyroxine treatment

Mesh:

Substances:

Year:  2016        PMID: 27473098     DOI: 10.1007/s12020-016-1035-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  54 in total

1.  Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions.

Authors:  Philippe Colucci; Pina D'Angelo; Giuseppe Mautone; Claudia Scarsi; Murray P Ducharme
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

Review 2.  A systematic review of drug absorption following bariatric surgery and its theoretical implications.

Authors:  R Padwal; D Brocks; A M Sharma
Journal:  Obes Rev       Date:  2009-06-02       Impact factor: 9.213

3.  Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients.

Authors:  M Giusti; L Mortara; N Machello; E Monti; G Pera; M Marenzana
Journal:  Drug Res (Stuttg)       Date:  2014-07-14

4.  Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches.

Authors:  Marco Centanni
Journal:  Endocrine       Date:  2012-10-25       Impact factor: 3.633

5.  Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Alessandro Antonelli
Journal:  Endocrine       Date:  2015-12-31       Impact factor: 3.633

6.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

7.  Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms.

Authors:  C S Yue; C Scarsi; M P Ducharme
Journal:  Arzneimittelforschung       Date:  2012-11-15

8.  Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium.

Authors:  Rakhi B Shah; Jarrod S Collier; Vilayat A Sayeed; Arthur Bryant; Muhammad J Habib; Mansoor A Khan
Journal:  AAPS PharmSciTech       Date:  2010-08-26       Impact factor: 3.246

Review 9.  The administration of L-thyroxine as soft gel capsule or liquid solution.

Authors:  Roberto Vita; Poupak Fallahi; Alessandro Antonelli; Salvatore Benvenga
Journal:  Expert Opin Drug Deliv       Date:  2014-06-04       Impact factor: 6.648

10.  Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women.

Authors:  Carlo Cappelli; Roberto Negro; Ilenia Pirola; Elena Gandossi; Barbara Agosti; Maurizio Castellano
Journal:  Gynecol Endocrinol       Date:  2015-11-20       Impact factor: 2.260

View more
  28 in total

1.  Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Authors:  Rosarita Ferrara; Valentina Ientile; Vincenzo Arcoraci; Carmen Ferrajolo; Carlo Piccinni; Andrea Fontana; Salvatore Benvenga; Gianluca Trifirò
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

2.  Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari; Roberto Vita
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

3.  Intestinal absorption and buccal absorption of liquid levothyroxine.

Authors:  Salvatore Benvenga; Flavia Di Bari
Journal:  Endocrine       Date:  2017-03-07       Impact factor: 3.633

4.  Is levothyroxine requirement the same for tablet and soft gel formulations?

Authors:  Vincenzo Di Donna; Rosa Maria Paragliola; Chiara de Waure; Giampaolo Papi; Alfredo Pontecorvi; Salvatore Maria Corsello
Journal:  Endocrine       Date:  2017-05-02       Impact factor: 3.633

5.  Oral mucositis induced by treatment with soft gel formulation of levothyroxine.

Authors:  Erika Messina; Francesco Ferraù; Salvatore Cannavò
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

Review 6.  The emergence of levothyroxine as a treatment for hypothyroidism.

Authors:  James V Hennessey
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

7.  Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation.

Authors:  Carmela Peirce; Serena Ippolito; Alejandra Lanas; Marcella Pesce; Gilda Pontieri; Debora Arpaia; Giovanni Sarnelli; Bernadette Biondi
Journal:  Endocrine       Date:  2017-07-13       Impact factor: 3.633

Review 8.  Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?

Authors:  Marco Castellana; Carlo Castellana; Luca Giovanella; Pierpaolo Trimboli
Journal:  Endocrine       Date:  2020-01-17       Impact factor: 3.633

Review 9.  Thyroid hormone therapy for hypothyroidism.

Authors:  Bernadette Biondi; David S Cooper
Journal:  Endocrine       Date:  2019-08-01       Impact factor: 3.633

10.  Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care.

Authors:  Valeria Guglielmi; Alfonso Bellia; Elisa Bianchini; Gerardo Medea; Iacopo Cricelli; Paolo Sbraccia; Davide Lauro; Claudio Cricelli; Francesco Lapi
Journal:  Endocrine       Date:  2017-09-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.